<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="59802">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02327455</url>
  </required_header>
  <id_info>
    <org_study_id>140601409</org_study_id>
    <secondary_id>R01HL0121226</secondary_id>
    <nct_id>NCT02327455</nct_id>
  </id_info>
  <brief_title>Integrated RF and B-mode Deformation Analysis for 4D Stress Echocardiography</brief_title>
  <official_title>Integrated RF and B-mode Deformation Analysis for 4D Stress Echocardiography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The specific aim of this clinical trial is to translate the investigators new 4DE (three
      sptial dimensions pluse time) stress echocardiographic method to patients with coronary
      artery disease referred for clinically indicated dobutamine stress/rest echo to evaluate the
      reproducibility of the technique in this clinical setting.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2017</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With an Interpretable 4DE Image</measure>
    <time_frame>After Stress Echocardiography (Approximately 2 hours)</time_frame>
    <description>This outcome will measure feasibility. Data from images will be analyzed with the integrated speckle/shape tracking approach (the method uses boundary detection/shape tracking to quantify left ventricular myocardial deformation)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Stress Dobutamine Echocardiographic 4DE Image System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo their clinically indicated stress dobutamine echocardiographic studies using our standard clinical graded dobutamine stress imaging protcol, employing the iE33 4DE system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stress Dobutamine Echocardiographic using 4DE System</intervention_name>
    <arm_group_label>Stress Dobutamine Echocardiographic 4DE Image System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age, referred for clinically indicated dobutamine rest/stress
             TTE

          -  Provide written informed consent to participate in the study

          -  Availability for repease rest/stress TTE within on eweek of clinically indicated
             study

        Exclusion Criteria:

          -  Unable to give informed consent

          -  Unstable hemodynamics that would not allow for repease rest/stress dobutamine
             transthoracic imaging

          -  Recurrent life threatening arrhythmias

          -  Heart rate &gt;110 BPM

          -  Inadequate windows for transthoracic imagine

          -  Patients that have a narrow-angle glaucoma (contraindication for atropine)

          -  Change in cardiac medications or management including, coronary revascularization
             beween intial and repeat TTE study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Sinusas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Donna McMahon</last_name>
    <phone>203-785-5005</phone>
    <email>donna.mcmahon@yale.edu</email>
  </overall_contact>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 21, 2016</lastchanged_date>
  <firstreceived_date>November 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dobutamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
